Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports

Area of Science:

• Endocrinology
• Dermatology
• Pharmacology

Background:

• Glucagon-like peptide-1 (GLP-1) receptor agonists are effective antidiabetic agents with benefits like weight loss.
• Semaglutide, a GLP-1 receptor agonist, is approved for type II diabetes and obesity management.
• Hypersensitivity reactions are known for other GLP-1 agonists, but not previously reported for semaglutide.

Observation:

• Two patients developed dermal hypersensitivity reactions while on semaglutide treatment.
• Histological findings in both cases were suggestive of drug-induced hypersensitivity.
• Symptoms improved within one month of discontinuing semaglutide.

Findings:

• This is the first report of dermal hypersensitivity reactions associated with semaglutide use.
• The cases suggest a potential link between semaglutide and allergic skin reactions.
• Discontinuation of semaglutide led to symptom resolution in both patients.

Implications:

• Clinicians should be aware of the possibility of semaglutide-induced hypersensitivity reactions.
• Further investigation into the immunogenicity of semaglutide may be warranted.
• These findings contribute to the broader understanding of adverse events associated with GLP-1 receptor agonists.